Truxima (rituximab), Celltrion’s MabThera biosimilar, became the first oncology monoclonal antibody biosimilar to enter the European market in April 2017. Two months later, Sandoz’s Rixathon, a second MabThera biosimilar, launched in Europe. In this series, we track awareness and uptake of Truxima and Rixathon since launch, to understand how their entry will impact the NHL, CLL, and immune biologics market. Along with awareness, familiarity, and perception of Truxima and Rixathon, our analysis also looks at the drivers and barriers behind uptake of these agents. Promotional efforts are explored, as well as prescriber and nonprescriber profiles, and benchmarking against other biosimilars, to better understand the dynamics of the German biosimilars market.

Questions Answered:

  • Are German physicians aware of Truxima and Rixathon?
  • What are the drivers to prescribing Truxima and Rixathon? What is the current level of Truxima and Rixathon use, and how is that changing over time?
  • Has experience with Truxima and Rixathon changed physicians’ opinion of biosimilars?
  • Have physicians experienced pressure to prescribe Truxima and Rixathon to patients?
  • What promotional messages are sales representatives employing for Truxima, Rixathon, and MabThera?

Table of contents

  • Oncology & Immunology: Truxima/Rixathon Launch Tracking (Germany) Wave 2
    • Key Findings
      • Biosimilar Prescriber and Nonprescriber Profiles
        • Differences Between Truxima and Rixathon Prescribers and Nonprescribers
    • Benchmarking Truxima's and Rixathon's Launch Success vs. Other Biosimilar Launches
    • Market Access Analysis
      • Reimbursement of Biosimilars in Germany
      • Biosimilar Pricing
      • Drivers of Biosimilar Uptake
      • German Payers' Opinions on the Market Impact of Biosimilar Rituximab
    • Awareness and Perceptions of Truxima and Rixathon
      • Awareness of and Familiarity with Truxima and Rixathon
        • Unaided Awareness of Drugs for NHL, CLL, and RA
        • Familiarity with Biosimilars, Truxima, and Rixathon
      • Perceptions of Truxima and Rixathon
        • Physicians' Perception of Truxima's and Rixathon's Clinical Development
        • Physicians' Perception of Truxima's and Rixathon's Approved Indications
    • Trial and Use
      • Current Use of Truxima and Rixathon
        • Experience with NHL, CLL, and RA Drugs
        • Current Use of Truxima and Rixathon
        • Patient Types for Truxima and Rixathon
        • Satisfaction with Truxima and Rixathon
        • Current Patient Share of Truxima and Rixathon
      • Drivers of and Barriers to Truxima and Rixathon Use
        • Reasons to Prescribe Truxima and Rixathon
        • Reasons for Not Prescribing Truxima and Rixathon
        • Net Cost of Truxima and Rixathon
        • Prescriber Perception of Truxima's and Rixathon's Similarity to MabThera
        • Anticipated Time to Start Prescribing Truxima and Rixathon
    • External Factors Affecting Use
      • Sources of Pressure or Recommendations to Use Rixathon and Truxima
        • Sources of Pressure or Recommendations to Use Rituximab Biosimilars
        • Reference-Pricing Expectations
      • Patients' Acceptance of Truxima and Rixathon
    • Promotional Activity
      • Promotional Activity for Truxima and Rixathon
    • Future Use of Biosimilars
      • Willingness to Prescribe Novel Biosimilars
        • Likelihood to Prescribe Novel Biosimilars
        • Willingness to Prescribe Novel Rituximab Biosimilars
      • Future Patient Share Expectations for Truxima and Rixathon
    • Appendix
      • Background on the German Rituximab Market
        • Background on Truxima's Development and Marketing
        • Background on Rixathon's Development and Marketing
        • Current and Future Biosimilar Landscape
      • Market News
      • Methodology and Objectives
        • Objectives
        • Physician Research Methodology
        • Payer Research Methodology
      • Respondent Demographics
      • Abbreviations

Author(s): Hamzah Aideed, MSc

Hamzah Aideed is a Principal Analyst in the biosimilars team at Decision Resources Group. Hamzah’s responsibilities include conducting primary and secondary market research, generating key insights into biosimilars and the biopharmaceutical industry, and providing client support. His work in biosimilars encompasses four key therapy areas – immunology, oncology, endocrinology, and nephrology. Prior to joining DRG, Hamzah was a Senior Research Executive at Consulting at McCann Health, specializing in the design and execution of advanced qualitative and quantitative research methodologies, for bespoke ad-hoc consulting projects. He holds an in Biotechnology & Business Management from the University of Warwick and a in Biological Chemistry from Aston University.  


Related Reports

Biomarkers in Oncology | Access & Reimbursement | Detailed, Expanded Analysis: Multi-indication (US)

Biomarker-driven prescribing is paramount in key oncology indications. Biomarkers play an important role and are well-entrenched in indications such as non-small-cell lung cancer and malignant me...

View Details

Biosimilars | Current Treatment | Oncology

In July 2019, Amgen’s Kanjinti (trastuzumab biosimilar) and Mvasi (bevacizumab biosimilar) were the first monoclonal antibody (MAb

View Details

Biosimilars | Access & Reimbursement | Oncology

This report is available to find out more click the link and fill out the form to get more details.

View Details

Biosimilars | Emerging Biosimilars | Oncology: Trastuzumab Biosimilars Launch Tracking (Germany) Wave 3

Celltrion’s Herzuma was the first biosimilar of Roche’s Herceptin, a blockbuster HER2-targeted therapy, to launch in Europe. A few months later, three additional trastuzumab biosimila...

View Details